Previous Article | Next Article 
Infection and Immunity, February 1999, p. 964-967, Vol. 67, No. 2
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Functional Analysis of the Carboxy-Terminal Domain
of Bacillus anthracis Protective Antigen
Fabien
Brossier,
Jean-Claude
Sirard,
Chantal
Guidi-Rontani,
Edith
Duflot, and
Michele
Mock*
Unité Toxines et Pathogénie
Bactériennes, Institut Pasteur, 75724 Paris Cedex 15, France
Received 3 September 1998/Returned for modification 10 November
1998/Accepted 30 November 1998
 |
ABSTRACT |
Protective antigen (PA) is the common receptor-binding component of
the two anthrax toxins. We investigated the involvement of the PA
carboxy-terminal domain in the interaction of the protein with cells. A
deletion resulting in removal of the entire carboxy-terminal domain of
PA (PA608) or part of an exposed loop of 19 amino acids (703 to 722)
present within this domain was introduced into the pag
gene. PA608 did not induce the lethal-factor (LF)-mediated cytotoxic
effect on macrophages because it did not bind to the receptor. In
contrast, PA711- and PA705-harboring lethal toxins (9- and
16-amino-acid deletions in the loop, starting after positions 711 and
705, respectively) were 10 times less cytotoxic than wild-type PA.
After cleavage by trypsin, the mutant PA proteins formed heptamers and
bound LF. The capacity of PA711 and PA705 to interact with cells was
1/10 that of wild-type PA. In conclusion, truncation of the
carboxy-terminal domain or deletions in the exposed loop resulted in PA
that was less cytotoxic or nontoxic because the mutated proteins did
not efficiently bind to the receptor.
 |
TEXT |
Bacillus anthracis, a
spore-forming bacterium, is the causative agent of anthrax. The two
exotoxins are main virulence factors of the microorganism. These toxins
are composed of three proteins: the protective antigen (PA, 83 kDa),
the lethal factor (LF, 85 kDa), and the edema factor (EF, 89 kDa)
(7, 15). Intravenous injection of the lethal toxin (PA plus
LF) causes sudden death in animals (1). The edema toxin (PA
plus EF) causes edema at the inoculation site (29). The
components PA, LF, and EF are encoded by the pag,
lef, and cya genes, respectively, and these genes
are carried by virulence plasmid pXO1 (185 kbp) (3, 17, 20,
32). A mode of action has been proposed for anthrax toxins (13). PA binds to a ubiquitous proteinaceous cell receptor
which has yet to be identified (6). It is then cleaved by a
furin-like protease into PA63 and PA20 (a 20-kDa amino-terminal
fragment) (11, 26). This processing facilitates the
heptamerization of PA63 (19) and the subsequent binding of
EF or LF. These toxic complexes are internalized by receptor-mediated
endocytosis. The pH within the acidic vesicles decreases during
intracellular trafficking, resulting in the insertion of PA into the
membrane and the formation of a channel (2, 12, 18). EF and
LF are further translocated into the cytoplasm to exert their catalytic
effects. EF is a calmodulin-dependent adenylate cyclase
(14). LF is a zinc metalloprotease which cleaves mitogen-activated protein kinase kinases 1 and 2 (5, 10, 31). The lethal toxin induces the lysis of macrophage cell lines such as RAW264.7 (8). PA is therefore a key protein,
promoting both the binding of the toxins and the translocation of their enzymatic moieties (27, 33). Previous studies have suggested that the carboxy-terminal extremity of PA is involved in the
recognition of the cell receptor (16, 28). The
three-dimensional structure of the monomeric PA has been solved at 2.1 Å resolution (21) and consists of four folding domains.
Domain 4 of PA encompasses the last 139 carboxy-terminal amino acids
(596 to 735). We analyzed the function of domain 4 in toxicity by
constructing various deletions in the pag gene, based on the
structural organization of the molecule. The cytotoxicity of the
resulting protein products in the presence of LF and their interaction
with the receptor were tested.
Construction of carboxy-terminal domain mutant PA.
Domain 4 of
PA contains an exposed loop of 19 amino acids which begins at position
703. Mutations affecting the whole of domain 4 of PA or the exposed
loop were produced (Fig. 1). We thereby created stop codons after the sequences encoding arginine 592 (PA592)
or aspartate 608 (PA608), removing the whole of domain 4 (PA592) or
retaining the first 16 amino acids of this domain (PA608). Two short,
in-frame deletions resulting in the removal of 9 (PA711) or 16 (PA705)
amino acids from the loop were created after the nucleotides encoding
residues 711 and 705, respectively. Mutants PA proteins were obtained
by site-directed mutagenesis with a PCR. Plasmid pACP41 was used as the
template for the PCR (23). The divergent sequences of the
primers used were 5'-AAGAAAATTTTAATCTTTTCTAAAAAAGGC-3' and
5'-GTTTTCTTTAGTAACAGCATATACATTTAC-3' for PA705,
5'-ACTAGGATTAATAATAGTGTTTTCTTTAG-3' and
5'-ATCAAGAAAATTTTAATCTTTTCTAAAAAAGGC-3' for PA711, and
5'-CTCACTAATCCGCCCCAACTGCTATG-3' and
5'-GGCTATGAGATAGGATAAGGTAATTCT-3' for PA608. For the
construction of PA592, a stop codon was introduced by using a
site-directed mutagenesis kit (Stratagene, La Jolla, Calif.). The
mutated pag genes, cloned into shuttle plasmid pAT28
(30), were transferred by heterogramic mating as previously
described (22) into PA-deficient B. anthracis
RP31 (23), and the production of PA-related proteins was
tested. The three mutated proteins, PA608, PA705, and PA711, were
purified by fast protein liquid chromatography as previously described
(23) from the supernatants of B. anthracis
transconjugants grown in R medium (24) containing tryptone
(5 g/liter). The molecular masses of the corresponding proteins were as
expected (approximately 83 kDa for PA711 and PA705 and 70 kDa for
PA608) (Fig. 2). In contrast, PA592 was
not found in the supernatants of B. anthracis, suggesting
that the amino acids between asparagine 592 and aspartate 608 are
required for stability of the molecule.

View larger version (47K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic representation of the mutagenesis of domain 4 of PA. The three-dimensional structure of the carboxy-terminal domain
of PA (amino acids 592 to 735), according to Petosa et al.
(21), is shown. We truncated the PA molecule by introducing
a stop codon after the codon encoding arginine 592 or aspartate 608. Two in-frame deletions resulting in the removal of 9 and 16 amino acids
(residues 711 to 721 and 705 to 722, respectively) were also created in
the exposed loop of 19 amino acids (residues 703 to 722). Point
mutations are indicated by dashed arrows; deletions are indicated by
plain arrows.
|
|

View larger version (57K):
[in this window]
[in a new window]
|
FIG. 2.
Trypsin treatment of mutant PA. Wild-type and mutant PA
proteins were purified from B. anthracis supernatants and
studied in native form ( ) or after (+) cleavage by trypsin. Samples
(2 µg) were subjected to electrophoresis in a sodium dodecyl
sulfate-12% polyacrylamide gel and stained with Coomassie blue. The
values on the left are molecular masses in kilodaltons.
|
|
Cytotoxicity of mutant PA in the presence of LF.
We tested the
ability of PA mutant proteins to induce LF-mediated lysis of murine
macrophage cell line RAW264.7 (Fig. 3). A
20-ng/ml concentration of wild-type PA was required for lysis of half
of the macrophages (50% effective concentration [EC50]). PA608 was completely inactive against macrophages (EC50,
>2 × 104 ng/ml). PA711 and PA705 were mildly toxic,
with EC50s of 2 × 102 and 6 × 102 ng/ml, respectively (EC50 of PA, 20 ng/ml).
To determine which step of the intoxication process was affected, we
analyzed the interaction of the mutant PA with LF and with the cell
receptor.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 3.
Cytotoxicity assay for mutant PA. Wild-type or mutated
PA protein (from 1 × 2 × 104 to 2 × 104 ng/ml) was serially diluted into a 96-well plate
containing RAW264.7 cells in the presence of a constant concentration
of LF (2 × 104 ng/ml). The cells were incubated for
3 h, and their viability was assessed by using a
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay
(9). The experiment was carried out at least three times for
each mutant PA protein.
|
|
Interaction of mutant PA with LF.
The interaction between PA
and LF requires the proteolytic processing of PA by the furin-like
protease. In vitro, trypsin mimics this action, cleaving PA into PA20
and PA63. Treatment of PA705, PA711, and PA608 with trypsin (600:1) for
30 min at 30°C released PA20 and a PA63 mutant polypeptide of the
expected size (Fig. 2). Thus, the trypsin-sensitive site was exposed in the mutant molecules. Moreover, PA705 and PA711 formed heptamers after
processing, as previously observed for wild-type PA (19) (data not shown). An assay was developed to detect the binding of LF to
the mutant PA molecules. Purified LF protein (1 µg per well) was
subjected to electrophoresis in a nondenaturing polyacrylamide gel and
transferred to a nitrocellulose membrane (Hybond-C; Amersham, Buckinghamshire, England). Wild-type or mutated PA proteins (2 µg/ml), freshly treated with trypsin, were incubated with the LF
blots for 16 h at 4°C. The PA63-LF complex was detected by Western blotting using rabbit anti-PA serum, followed by the addition of goat anti-immunoglobulin G coupled to peroxidase (ECL kit; Amersham). Only the trypsin-treated forms of the PA proteins recognized LF on the membrane (Fig. 4). A double
signal was routinely observed which corresponded to the two isoforms of
LF. The three mutant proteins interacted with LF in a manner similar to
that of wild-type PA. Thus, (i) the conformation of the LF-binding
region of PA was not significantly changed and (ii) domain 4 of PA was
not required for the binding of LF, consistent with previous reports (16, 28).

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 4.
Interaction of mutant PA proteins with LF. Purified LF
protein was subjected to electrophoresis in a 10% nondenaturing
polyacrylamide gel and transferred to a nitrocellulose membrane under
nondenaturing conditions. Wild-type or mutated PA proteins (2 µg),
untreated ( ) or treated (+) with trypsin, were added. The filter was
incubated for 16 h at 4°C, and the LF-PA63 complex was detected
with anti-PA serum.
|
|
Binding of mutant PA to cells.
The binding of wild-type and
mutant PA proteins to cells was tested on CHO-K1 cells, each of which
has approximately 10,000 PA receptor molecules on its surface
(6). An enzyme-linked immunosorbent assay was used to
determine protein binding. The CHO-K1 cell line was seeded into 24-well
plates (Costar) containing glass slides at a density of approximately
105 cells per well. The cells were incubated for 16 h
at 37°C in a 5% CO2-95% air atmosphere, cooled for 15 min at 4°C, washed with cold phosphate-buffered saline (PBS), and
incubated for 3 h at 4°C in RPMI 1640 with wild-type or mutant
PA protein. Unbound proteins were removed by washing the cells with
cold PBS. Cells were then fixed and then incubated with anti-PA serum
(1/4,000) for 45 min at 37°C in PBS-skim milk powder (2%). After
washing, goat anti-immunoglobulin G coupled to
-galactosidase
(1/10,000) was added and incubated with cells in PBS-skim milk powder
(2%) for 45 min at 37°C. The glass slides were washed with PBS and incubated for 30 min at 37°C with methylumbelliferyl-
-galactoside (MUG). The enzymatic reaction was stopped by addition of 100 mM glycine
(pH 10.4). The hydrolysis of MUG by the
-galactosidase resulted in
the formation of a fluorescent component. The level of fluorescence
associated with cells was assessed on a fluoroscan fluorimeter
(Titertek-Fluoroskan, Labsystem).
The threshold for detection of wild-type PA was about 10 ng/ml, and the
receptors were saturated at a concentration of 5 µg/ml
(Fig.
5). The truncated protein, PA608, did not
bind to cells,
even at high concentrations (10
4 ng/ml), and
the level of binding of PA711 and PA705 to cells
was significantly
lower (1/10) than that of the wild-type protein.
Therefore, the low
cytotoxicity of domain 4 mutant PA is due to
a defect in the receptor
interaction of these molecules. The 19-amino-acid
loop of PA is
structurally similar to the 15-amino-acid (from
residue 516 to residue
530) exposed loop in the binding domain
of the diphtheria toxin
(
4). Replacement of Lys 516 and Phe
530 with Ala results in
mutant diphtheria toxins that are 22 and
10 times less cytotoxic than
the wild-type protein, respectively,
because the molecules do not
efficiently bind to the receptor
(
25). The exposed loops of
PA and the diphtheria toxin may have
similar functions. They may be
involved in stabilization of the
toxin-receptor complex or may
participate in receptor recognition.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 5.
Assay of binding of wild-type or mutant PA proteins to
CHO-K1 cells. Various concentrations of wild-type or mutant PA proteins
(from 10 to 1 × 104 ng/ml) were incubated with CHO-K1
cells for 3 h at 4°C. The binding of PA proteins to cells was
detected with anti-PA serum and a secondary antibody coupled to
-galactosidase. MUG was added as the substrate for
-galactosidase, and fluorescence was quantified with a fluorimeter.
The experiment was carried out at least three times for each mutant PA
protein.
|
|
 |
ACKNOWLEDGMENTS |
We are grateful to Carlo Petosa for helpful discussions on the
design of mutant PA proteins. We also thank Evelyne Tosi-Couture for
the observations by electron microscopy and Guy Patra for helpful
discussions on the purification of the mutant PA proteins.
This work was supported by DRET (94-118). F.B. was supported by the
Ministère de l'Enseignement Supérieur et de la Recherche.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Unité
Toxines et Pathogénie Bactériennes (URA 1858, CNRS),
Institut Pasteur, 28, rue du Dr. Roux, 75724 Paris Cedex 15, France.
Phone: (33) 1.45.68.83.12. Fax: (33) 1.45.68.89.54. E-mail:
mmock{at}pasteur.fr.
Editor:
J. T. Barbieri
 |
REFERENCES |
| 1.
|
Beall, F. A.,
M. J. Taylor, and C. B. Thorne.
1962.
Rapid lethal effects in rats of a third component found upon fractionating the toxin of Bacillus anthracis.
J. Bacteriol.
83:1274-1280[Abstract/Free Full Text].
|
| 2.
|
Blaustein, R. O.,
T. M. Koehler,
R. J. Collier, and A. Finkelstein.
1989.
Anthrax toxin: channel-forming activity of protective antigen in planar phospholipid bilayers.
Proc. Natl. Acad. Sci. USA
86:2209-2213[Abstract/Free Full Text].
|
| 3.
|
Bragg, T. S., and D. L. Robertson.
1986.
Nucleotide sequence and analysis of the lethal factor gene (lef) from Bacillus anthracis.
Gene
81:45-54.
|
| 4.
|
Choe, S.,
M. J. Bennett,
G. Fujii,
P. M. G. Curmi,
K. A. Kantardjieff,
R. J. Collier, and D. Eisenberg.
1992.
The crystal structure of diphtheria toxin.
Nature
357:216-222[Medline].
|
| 5.
|
Duesbery, N. S.,
C. P. Webb,
S. H. Leppla,
V. M. Gordon,
K. R. Klimpel,
T. D. Copeland,
N. G. Ahn,
M. K. Oskarsson,
K. Fukasawa,
K. D. Paull, and G. F. Vandewoude.
1998.
Proteolytic inactivation of map-kinase-kinase by anthrax lethal factor.
Science
280:734-737[Abstract/Free Full Text].
|
| 6.
|
Escuyer, V., and R. J. Collier.
1991.
Anthrax protective antigen interacts with a specific receptor on the surface of CHO-K1 cells.
Infect. Immun.
59:3381-3386[Abstract/Free Full Text].
|
| 7.
|
Fish, D. C.,
B. G. Mahlandt,
J. P. Dobbs, and R. E. Lincoln.
1968.
Purification and properties of in vitro-produced anthrax toxin components.
J. Bacteriol.
95:907-918[Abstract/Free Full Text].
|
| 8.
|
Friedlander, A. M.
1986.
Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process.
J. Biol. Chem.
261:7123-7126[Abstract/Free Full Text].
|
| 9.
|
Hansen, M. B.,
S. E. Nielsen, and K. Berg.
1989.
Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill.
J. Immunol. Methods
119:203-210[Medline].
|
| 10.
|
Klimpel, K. R.,
N. Arora, and S. H. Leppla.
1994.
Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity.
Mol. Microbiol.
13:1093-1100[Medline].
|
| 11.
|
Klimpel, K. R.,
S. S. Molloy,
G. Thomas, and S. H. Leppla.
1992.
Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin.
Proc. Natl. Acad. Sci. USA
89:10277-10281[Abstract/Free Full Text].
|
| 12.
|
Koehler, T. M., and R. J. Collier.
1991.
Anthrax toxin protective antigen: low pH-induced hydrophobicity and channel formation in liposomes.
Mol. Microbiol.
5:1501-1506[Medline].
|
| 13.
|
Leppla, S. H.
1991.
The anthrax toxin complex, p. 277-302.
In
J. E. Alouf, and J. H. Freer (ed.), Sourcebook of bacterial protein toxins, vol. 14. Academic Press, San Diego, Calif.
|
| 14.
|
Leppla, S. H.
1982.
Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations in eukaryotic cells.
Proc. Natl. Acad. Sci. USA
79:3162-3166[Abstract/Free Full Text].
|
| 15.
|
Leppla, S. H.
1988.
Production and purification of anthrax toxin.
Methods Enzymol.
165:103-116[Medline].
|
| 16.
|
Little, S. F.,
J. M. Novak,
J. R. Lowe,
S. H. Leppla,
Y. Singh,
K. R. Klimpel,
B. C. Lidgerding, and A. M. Friedlander.
1996.
Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies.
Microbiology (Reading)
142:707-715[Abstract/Free Full Text].
|
| 17.
|
Mikesell, P.,
B. E. Ivins,
J. D. Ristroph, and T. M. Dreier.
1983.
Evidence for plasmid-mediated toxin production in Bacillus anthracis.
Infect. Immun.
39:371-376[Abstract/Free Full Text].
|
| 18.
|
Milne, J. C., and R. J. Collier.
1993.
pH-dependent permeabilization of the plasma membrane of mammalian cells by anthrax protective antigen.
Mol. Microbiol.
10:647-653[Medline].
|
| 19.
|
Milne, J. C.,
D. Furlong,
P. C. Hanna,
J. S. Wall, and R. J. Collier.
1994.
Anthrax protective antigen forms oligomers during intoxication of mammalian cells.
J. Biol. Chem.
269:20607-20612[Abstract/Free Full Text].
|
| 20.
|
Mock, M.,
E. Labruyère,
P. Glaser,
A. Danchin, and A. Ullmann.
1988.
Cloning and expression of the calmodulin-sensitive Bacillus anthracis adenylate cyclase in Escherichia coli.
Gene
64:277-284[Medline].
|
| 21.
|
Petosa, C.,
R. J. Collier,
K. R. Klimple,
S. H. Leppla, and R. Lidington.
1997.
Crystal structure of the anthrax toxin protective antigen.
Nature
385:933-938.
|
| 22.
|
Pezard, C.,
P. Berche, and M. Mock.
1991.
Contribution of individual toxin components to virulence of Bacillus anthracis.
Infect. Immun.
59:3472-3477[Abstract/Free Full Text].
|
| 23.
|
Pezard, C.,
E. Duflot, and M. Mock.
1993.
Construction of Bacillus anthracis mutant strains producing a single toxin component.
J. Gen. Microbiol.
139:2459-2463[Abstract/Free Full Text].
|
| 24.
|
Ristroph, J. D., and B. E. Ivins.
1983.
Elaboration of Bacillus anthracis antigens in a new, defined culture medium.
Infect. Immun.
39:483-486[Abstract/Free Full Text].
|
| 25.
|
Shen, W. H.,
S. Y. Choe,
D. Eisenberg, and R. J. Collier.
1994.
Participation of lysine 516 and phenylalanine 530 of diphtheria toxin in receptor recognition.
J. Biol. Chem.
269:29077-29084[Abstract/Free Full Text].
|
| 26.
|
Singh, Y.,
V. K. Chaudhary, and S. H. Leppla.
1989.
A deleted variant of Bacillus anthracis protective antigen is non-toxic and blocks anthrax toxin in vivo.
J. Biol. Chem.
264:19103-19107[Abstract/Free Full Text].
|
| 27.
|
Singh, Y.,
K. R. Klimpel,
N. Arora,
M. Sharma, and S. H. Leppla.
1994.
The chymotrypsin-sensitive site, FFD315, in anthrax toxin protective antigen is required for translocation of lethal factor.
J. Biol. Chem.
269:29039-29046[Abstract/Free Full Text].
|
| 28.
|
Singh, Y.,
K. R. Klimpel,
C. P. Quinn,
V. K. Chaudhary, and S. H. Leppla.
1991.
The carboxyl-terminal end of protective antigen is required for receptor binding and anthrax toxin activity.
J. Biol. Chem.
266:15493-15497[Abstract/Free Full Text].
|
| 29.
|
Stanley, J. L., and H. Smith.
1961.
Purification of factor I and recognition of a third factor of anthrax toxin.
J. Gen. Microbiol.
26:49-66[Abstract/Free Full Text].
|
| 30.
|
Trieu-Cuot, P.,
C. Carlier,
C. Poyart-Salmeron, and P. Courvalin.
1990.
A pair of mobilisable shuttle vectors conferring resistance to spectinomycin for molecular cloning in Escherichia coli and Gram positive bacteria.
Nucleic Acids Res.
18:4296[Free Full Text].
|
| 31.
|
Vitale, G.,
R. Pellizzari,
C. Recchi,
G. Napolitani,
M. Mock, and C. Montecucco.
1998.
Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages.
Biochem. Biophys. Res. Commun.
248:706-711[Medline].
|
| 32.
|
Vodkin, M. H., and S. H. Leppla.
1983.
Cloning of the protective antigen gene of Bacillus anthracis.
Cell
34:693-697[Medline].
|
| 33.
|
Wang, W.-M.,
R. Wattiez,
F. Brossier,
M. Mock,
P. Falmagne,
J.-M. Ruysschaert, and V. Cabiaux.
1998.
Use of a photoactivatable lipid to probe the topology of PA63 of Bacillus anthracis in lipid membranes.
Eur. J. Biochem.
256:179-183[Medline].
|
Infection and Immunity, February 1999, p. 964-967, Vol. 67, No. 2
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Chen, K.-H., Liu, S., Bankston, L. A., Liddington, R. C., Leppla, S. H.
(2007). Selection of Anthrax Toxin Protective Antigen Variants That Discriminate between the Cellular Receptors TEM8 and CMG2 and Achieve Targeting of Tumor Cells. J. Biol. Chem.
282: 9834-9845
[Abstract]
[Full Text]
-
Zomber, G., Reuveny, S., Garti, N., Shafferman, A., Elhanany, E.
(2005). Effects of Spontaneous Deamidation on the Cytotoxic Activity of the Bacillus anthracis Protective Antigen. J. Biol. Chem.
280: 39897-39906
[Abstract]
[Full Text]
-
Brossier, F., Levy, M., Landier, A., Lafaye, P., Mock, M.
(2004). Functional Analysis of Bacillus anthracis Protective Antigen by Using Neutralizing Monoclonal Antibodies. Infect. Immun.
72: 6313-6317
[Abstract]
[Full Text]
-
Lacy, D. B., Wigelsworth, D. J., Melnyk, R. A., Harrison, S. C., Collier, R. J.
(2004). Structure of heptameric protective antigen bound to an anthrax toxin receptor: A role for receptor in pH-dependent pore formation. Proc. Natl. Acad. Sci. USA
101: 13147-13151
[Abstract]
[Full Text]
-
Barth, H., Aktories, K., Popoff, M. R., Stiles, B. G.
(2004). Binary Bacterial Toxins: Biochemistry, Biology, and Applications of Common Clostridium and Bacillus Proteins. Microbiol. Mol. Biol. Rev.
68: 373-402
[Abstract]
[Full Text]
-
Mourez, M., Yan, M., Lacy, D. B., Dillon, L., Bentsen, L., Marpoe, A., Maurin, C., Hotze, E., Wigelsworth, D., Pimental, R.-A., Ballard, J. D., Collier, R. J., Tweten, R. K.
(2003). Mapping dominant-negative mutations of anthrax protective antigen by scanning mutagenesis. Proc. Natl. Acad. Sci. USA
100: 13803-13808
[Abstract]
[Full Text]
-
Rosovitz, M. J., Schuck, P., Varughese, M., Chopra, A. P., Mehra, V., Singh, Y., McGinnis, L. M., Leppla, S. H.
(2003). Alanine-scanning Mutations in Domain 4 of Anthrax Toxin Protective Antigen Reveal Residues Important for Binding to the Cellular Receptor and to a Neutralizing Monoclonal Antibody. J. Biol. Chem.
278: 30936-30944
[Abstract]
[Full Text]
-
Flick-Smith, H. C., Walker, N. J., Gibson, P., Bullifent, H., Hayward, S., Miller, J., Titball, R. W., Williamson, E. D.
(2002). A Recombinant Carboxy-Terminal Domain of the Protective Antigen of Bacillus anthracis Protects Mice against Anthrax Infection. Infect. Immun.
70: 1653-1656
[Abstract]
[Full Text]
-
Mogridge, J., Mourez, M., Collier, R. J.
(2001). Involvement of Domain 3 in Oligomerization by the Protective Antigen Moiety of Anthrax Toxin. J. Bacteriol.
183: 2111-2116
[Abstract]
[Full Text]
-
Brossier, F., Weber-Levy, M., Mock, M., Sirard, J.-C.
(2000). Role of Toxin Functional Domains in Anthrax Pathogenesis. Infect. Immun.
68: 1781-1786
[Abstract]
[Full Text]